Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models-Reference-Cited by-同舟云学术

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

Published:2017-03-31 Issue:15 Volume:23 Page:4335-4346
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Suominen Mari I.,Fagerlund Katja M.,Rissanen Jukka P.,Konkol Yvonne M.,Morko Jukka P.,Peng ZhiQi,Alhoniemi Esa J.,Laine Salla K.,Corey Eva,Mumberg Dominik,Ziegelbauer Karl,Käkönen Sanna-Maria,Halleen Jussi M.,Vessella Robert L.,Scholz Arne

Funder

National Institutes of Health

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review;Journal of Oncology Pharmacy Practice;2024-08-22

2. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice;Cancers;2024-07-21

3. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

4. The Different Strategies for the Radiolabeling of [211At]-Astatinated Radiopharmaceuticals;Pharmaceutics;2024-05-30

5. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer;Radiotherapy and Oncology;2024-03